The Phase 2 SANRECO topline readout for divesiran (PV) expected in August 2026 is the dominant catalyst. The narrowing loss and $72.1M cash position suggest manageable burn, but the company remains pre-commercialization. Traders should position for binary outcome at data readout; if positive, could unlock partner interest and re-rate the stock. If negative, the stock likely retraces to pre-pipeline-optimism levels.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 10 $15.43entry
- T+1 · 3mo ago −4.60%α −4.28% · $14.72
- T+5 · 3mo ago −7.00%α −6.95% · $14.35
- T+20 · 2mo ago −11.28%α −10.36% · $13.69
- T+60 · 14d ago +28.19%α +30.61% · $19.78
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Silence Therapeutics reported Q2 2026 net loss of $12.3M ($0.09 per share), narrower than the $27.4M loss in Q2 2025 and ahead of the $0.11 consensus. Cash burn slowed as R&D costs dropped 48% YoY to $9.1M. The key catalyst is the upcoming Phase 2 SANRECO topline readout for divesiran in polycythemia vera expected in August 2026, which will determine the stock's near-term trajectory.
Key Financial Metrics
Key Facts
- Net loss of $12.3M ($0.09/share) vs $27.4M ($0.19/share) in Q2 2025, narrower loss beats consensus of $0.11 loss
- Revenue $0.2M vs $0.4M in Q2 2025 (AstraZeneca collaboration), no consensus revenue figure available for comparison
- Cash and cash equivalents $72.1M as of June 30, 2026, up from $11.3M at Dec 31, 2025 (no new financings cited; likely reflects timing of R&D benefit receivable and cash burn)
- R&D expenses fell 48% YoY to $9.1M (from $17.6M) due to zerlasiran Phase 3 readiness completion and reduced personnel costs
- Phase 2 SANRECO trial (divesiran) for polycythemia vera patient dosing completed June 2026; topline results on-track for August 2026, binary catalyst
- SLN312 (AZD1705) Phase 1 results presented at EAS 2026; two preclinical programs (SLN365, SLN098) targeting IND filing in 2027
- No guidance or revenue/earnings estimates provided for upcoming periods
Financial Impact
Narrower-than-expected loss of $12.3M vs consensus EPS of $0.11 loss (approximately $15.4M), beats on EPS but revenue was less than half of prior quarter's $0.4M; cash position $72.1M provides runway through upcoming Phase 2 catalyst
Risk Factors
- Phase 2 SANRECO trial failure or underwhelming efficacy would materially depress the stock given divesiran is the lead candidate
- Revenue from AstraZeneca collaboration is minimal and unpredictable; company is entirely dependent on pipeline advancement
- No approved products; ongoing net losses with no clear path to profitability without a partnership or commercialization event
- Cash burn of ~$12-15M/quarter implies roughly 4-5 quarters of runway at $72.1M; may need to raise capital if pipeline timelines slip
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-341240 |
| Document: d162225d8k.htm | 0001193125-26-341240 |
| Document: 0001193125-26-341240-index-headers.html | 0001193125-26-341240 |
| Document: 0001193125-26-341240-index.html | 0001193125-26-341240 |
| Document: 0001193125-26-341240.txt | 0001193125-26-341240 |
| 8-K Data (Synthetic) | 0001193125-26-341240 |
Track record
15 reports on SLN
4 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +28.19% at T+60 after the Aug 10, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $19.72 Now $19.80 +0.42% settles Nov 24
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $19.80 Now $19.80 −0.00% settles Nov 19
- Nov 12, 20264d ago DEFA14A Neutral 4/10 Entry $19.80 Now $19.80 −0.00% settles Nov 19
- Nov 12, 20264d ago 8-K Neutral 5/10 Entry $19.80 Now $19.80 −0.00% settles Nov 19
- Nov 5, 202611d ago SC 13G Neutral 4/10 Entry $19.72 to $19.80 Now $19.80 +0.41% ▲ +0.41% −2.88% vs SPY
- Oct 19, 202628d ago DEFA14A Bullish 7/10 Entry $19.61 to $19.78 Now $19.80 +0.97% ▲ +0.87% +0.79% vs SPY
- Oct 19, 202628d ago DEFA14A Bullish 8/10 Entry $19.58 to $19.78 Now $19.80 +1.12% ▲ +1.02% +1.17% vs SPY
- Oct 19, 202628d ago 8-K Bullish 9/10 Entry $19.58 to $19.78 Now $19.80 +1.12% ▲ +1.02% +1.17% vs SPY
- Oct 13, 20264w ago SC 13G/A Neutral 3/10 Entry $8.98 to $19.67 Now $19.80 +120.49% ▲ +119.04% +118.59% vs SPY
- Oct 13, 20264w ago SC 13G Neutral 3/10 Entry $8.98 to $19.67 Now $19.80 +120.49% ▲ +119.04% +118.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers